This book serves as a unique resource on the field of novel drug delivery systems (NDDSs), catering to both academic audiences (researchers, teachers, students) and industry professionals (pharmaceutical policymakers, managers, R&D, regulatory, business development, and marketing) involved in NDDSs.
The evolving nature of diseases and the emergence of new health complications have driven a significant shift in drug therapy. Coupled with changes in human lifestyles and economic conditions, these factors have compelled the pharmaceutical industry to develop novel, efficient, and affordable drug products. The rise of promising technologies aimed at enhancing therapeutic performance further underscores the importance of novel drug delivery systems (NDDSs), making this field one of the most dynamic in pharmaceutical sciences today.
This book offers a comprehensive exploration of NDDS applications, catering to both academic and industry professionals. It is designed to be both user-friendly and thorough, meeting the needs of diverse readers—from those seeking practical insights to those delving deeply into the field’s various sectors. The content has been meticulously compiled, organized, and analyzed by a team of experts to ensure accuracy, relevance, and currency. The book provides up-to-date information suitable for a broad audience, reflecting the wide scope of the NDDS field.
The first section covers the foundational principles of NDDS, including their scientific and therapeutic basis, as well as the epidemiological and economic trends driving their development. Subsequent sections explore market-oriented aspects, such as global trends and projections. Chapters 3 to 12 present a taxonomy of NDDS categorized by their routes of administration. The book concludes with a forward-looking report on the potential future directions of NDDS.
Written in clear, concise language, the book is accessible to non-native English readers, ensuring broad usability. Original figures, created by experts with scientific and graphic design expertise, enhance the reading experience and aid in understanding complex concepts.
Audience
A wide variety of professional readers from universities and other research institutions to health industries (industrial pharmaceutical and related), to the relevant high-tech startups to health and pharma policymakers and managers will be among the audiences of this book.
Mehrdad Hamidi, PhD, obtained his doctorate from the Tehran University of Medical Sciences, Tehran, Iran in 1999. His main research field is novel delivery systems focusing on BBB transport of CNS-active drugs. He has published many articles in international journals, two books, multiple book chapters, three contributions to an encyclopedia, and 5 US patents. Concurrently, he is a member of the Iranian Academy of Medical Sciences, the Founding Chairman and Founding CEO of two knowledge-based entrepreneurial pharmaceutical companies, and the Chair of the Iranian Association of Pharmaceutical Scientists.
Mahsa Sayed Tabatabaei, PhD, obtained her doctorate at Shahid Behesthi University of Medical Sciences, Iran in 2022. She is currently a pharmaceutical R&D Project Manager at Hida Pharma in Tehran engaged in different nanotechnology-based drug delivery projects, mainly drug self-delivery systems, peptide and protein delivery, self-assembled nanostructures, and novel cosmeceuticals.
